Cantor Fitzgerald tells investors that MariTide’s Phase 1 data includes “a big surprise” as the supplemental appendix file ...

Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Amgen stock tumbled late Tuesday on a report that its high-profile weight-loss shot, MariTide, could be linked to bone ...

(Reuters) - U.S. stock index futures dipped on Tuesday after Wall Street's rally over the past few days following election ...

The endorsement reflects Amgen’s progress amid a pivotal year, especially with Phase 2 obesity data for MariTide expected by ...

The S&P 500 slipped 0.3% on Tuesday, Nov. 12, the benchmark index's first negative trading day since last week's election.

Jefferies reviewed public data from the Phase 1 trial of AMG-133 showing additional measurements of bone density from obesity patients, which ...